Articles by Kerri Fitzgerald
The phase II, multicenter, single-arm study is assessing axi-cel for frontline treatment in patients with high-risk LBCL.
The analysis assessed the impacts of bridging therapy when used in patients receiving axi-cel for large B-cell lymphoma.
Pirtobrutinib is a non-covalent (reversible) BTK inhibitor that inhibits both wild-type and C481-mutant BTK.
Study authors noted that the findings underscore the need for tailored approaches to MRD testing.
The FDA approves the first bispecific antibody for relapsed/refractory DLBCL.
The FDA approved the first and only noncovalent BTK inhibitor for MCL.
Race/ethnicity, income, and access to chemotherapy and radiation therapy improved outcomes in patients with Burkitt lymphoma.
The cell of origin in patients with diffuse large B-cell lymphoma may impact their response to CAR-T therapy and survival.
Mutation of CALR in patients with myelofibrosis may be associated with a more anemic phenotype at diagnosis.
Simultaneous treatment with ponatinib and blinatumomab was safe and effective in patients with newly diagnosed PH+ ALL.
The combination of decitabine/cedazuridine, venetoclax, and an IDH1 inhibitor was effective in treating IDH-mutated AML.
Ivosidenib and azacitidine led to deep and durable remissions associated with clearance of IDH1-mutated newly diagnosed AML.
The REALYSA study has garnered an enrollment rate of 54%—higher than typical clinical trial inclusion rates.
Selinexor plus ruxolitinib demonstrated promising clinical activity in patients with treatment-naïve myelofibrosis.
A new study presented at the 2022 ASH Annual Meeting identified causes of the increased myeloma risk in Black Americans.
The combination of interferon and ruxolitinib may be a treatment option for newly diagnosed polycythemia vera.
Momelotinib led to an increased likelihood of becoming transfusion-independent compared with danazol in myelofibrosis.
The VIALE-A trial showed a sustained OS benefit in patients with AML who received venetoclax and azacitidine,
Venetoclax plus HMAs led to higher response rates than non-venetoclax regimens in patients with newly diagnosed AML.
Courtney D. DiNardo, MD, MSCE, talks about mentorship and her research on hereditary cancer predisposition syndromes.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.